Skip to main content
. 2014 Aug 26;307(9):E773–E783. doi: 10.1152/ajpendo.00148.2014

Table 3.

SRC1 ASO treatment increases the expression of the insulin-sensitizing factor PGDS

Control ASO SRC1 ASO P Value
L-PGDS 2.2 ± 1.03 17.28 ± 7.4 0.04
H-PGDS 1.07 ± 0.16 1.58 ± 0.42 0.24
Leptin 1.17 ± 0.24 0.69 ± 0.19 0.14
RBP4 1.04 ± 0.11 0.82 ± 0.11 0.19
Resistin 1.04 ± 0.11 1.23 ± 0.18 0.38
PPARγ 1.1 ± 0.19 0.65 ± 0.15 0.10
CIDEA 1.05 ± 0.13 0.97 ± 0.11 0.65
ACOX1 1.09 ± 0.18 0.80 ± 0.07 0.17
PNPLA3 1.09 ± 0.18 0.33 ± 0.05 0.002
PEPCK 1.06 ± 0.14 0.39 ± 0.07 0.001
LPL 1.11 ± 0.2 0.92 ± 0.08 0.41

Values are mean fold change ± SE; n = 6–8/group. L-PGDS, lipocalin type prostaglandin D2 synthase; H-PGDS, hematopoietic type prostaglandin D2 synthase; RBP4, retinol-binding protein-4; PPARγ, peroxisome proliferator-activated receptor-α; CIDEA, cell death-inducing DNA fragmentation factor α-subunit-like effector A; ACOX1, acyl-CoA oxidase 1; PNPLA3, phospholipase domain-containing 3; PEPCK, phospoenolpyruvate carboxykinase; LPL, lipoprotein lipase. Sprague-Dawley rats were treated with control or SRC1 ASO and fed a regular chow diet for 4 wk. Real-time PCR analysis of mRNA expression in the white adipose tissue of hyperinsulinemic euglycemic-clamped rats. P value calculated by Student's t-test.